Researchers track lethal prostate cancer to determine clonal origin

Prostate cancer has variable manifestations, ranging from relatively benign localized tumors to widespread life-threatening metastases. The origin of most prostate cancer metastases can be traced back to the primary tumor; therefore, understanding the mutations in the primary tumor that promote cancer spread is of great interest.

In this issue of the Journal of Clinical Investigation, Srinivasan Yegnasubramanian and colleagues at Johns Hopkins University track the development of lethal in a patient. Using tissue samples taken throughout the progression of the cancer, the authors identified the origin of the lethal clone. Surprisingly, in this case the lethal clone originated from a small, low-grade foci in the and not from the larger high-grade region of the tumor.

In the accompanying commentary, Rose Brannon and Charles Sawyers of Memorial Sloan-Kettering Cancer Center discuss the importance of individual case studies and how a comprehensive database of such studies is needed to identify common patterns in .

More information: Tracking the clonal origin of lethal prostate cancer, J Clin Invest. DOI: 10.1172/JCI70354
"N of 1" case reports in the era of whole-genome sequencing, J Clin Invest. 2013;123(11):4568–4570. DOI: 10.1172/JCI70935

Related Stories

Mayo Clinic genomic analysis lends insight to prostate cancer

date May 23, 2013

Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...

Recommended for you

Using healthy skin to identify cancer's origins

date 16 hours ago

Normal skin contains an unexpectedly high number of cancer-associated mutations, according to a study published in Science. The findings illuminate the first steps cells take towards becoming a cancer and de ...

Gender differences in receipt of end-of-life care

date 16 hours ago

(HealthDay)—There are gender differences in receipt of end-of-life (EoL) care among terminally ill cancer patients, with male patients more likely to receive intensive care unit (ICU) care, according to ...

Scientists unveil prostate cancer's 'Rosetta Stone'

date 18 hours ago

Almost 90 per cent of men with advanced prostate cancer carry genetic mutations in their tumours that could be targeted by either existing or new cancer drugs, a landmark new study reveals.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.